DK3404043T3 - Anti-cdh3-antistof med høj internaliseringskapacitet - Google Patents
Anti-cdh3-antistof med høj internaliseringskapacitet Download PDFInfo
- Publication number
- DK3404043T3 DK3404043T3 DK18182161.2T DK18182161T DK3404043T3 DK 3404043 T3 DK3404043 T3 DK 3404043T3 DK 18182161 T DK18182161 T DK 18182161T DK 3404043 T3 DK3404043 T3 DK 3404043T3
- Authority
- DK
- Denmark
- Prior art keywords
- cdh3 antibody
- internalization capacity
- high internalization
- capacity
- cdh3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010243708 | 2010-10-29 | ||
JP2011150812 | 2011-07-07 | ||
EP11836461.1A EP2634194B1 (en) | 2010-10-29 | 2011-10-28 | Anti-cdh3 antibody having high internalization capacity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3404043T3 true DK3404043T3 (da) | 2022-11-14 |
Family
ID=45994030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18182161.2T DK3404043T3 (da) | 2010-10-29 | 2011-10-28 | Anti-cdh3-antistof med høj internaliseringskapacitet |
DK11836461.1T DK2634194T3 (da) | 2010-10-29 | 2011-10-28 | Anti-cdh3-antistof med høj internaliseringskapacitet |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11836461.1T DK2634194T3 (da) | 2010-10-29 | 2011-10-28 | Anti-cdh3-antistof med høj internaliseringskapacitet |
Country Status (14)
Country | Link |
---|---|
US (1) | US9328160B2 (da) |
EP (3) | EP2634194B1 (da) |
JP (2) | JP6006640B2 (da) |
CY (1) | CY1121061T1 (da) |
DK (2) | DK3404043T3 (da) |
ES (2) | ES2690469T3 (da) |
HR (1) | HRP20181438T1 (da) |
HU (1) | HUE039375T2 (da) |
LT (1) | LT2634194T (da) |
PL (2) | PL2634194T3 (da) |
PT (1) | PT2634194T (da) |
RS (1) | RS57646B1 (da) |
SI (1) | SI2634194T1 (da) |
WO (1) | WO2012057328A1 (da) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130136689A1 (en) * | 2007-06-05 | 2013-05-30 | Christian Rohlff | Proteins |
US20130058947A1 (en) * | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
US9764041B2 (en) * | 2012-04-04 | 2017-09-19 | Perseus Proteomics Inc. | Drug conjugate comprising anti-CDH3 (P-cadherin) antibody |
RU2015139147A (ru) * | 2013-02-15 | 2017-03-21 | Персеус Протеомикс Инк. | Гуманизированное антитело к cdh3, его конъюгат с лекарственным средством и их применение |
JPWO2015108203A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社オーダーメードメディカルリサーチ | 抗slc6a6抗体を用いたがん治療用医薬組成物 |
MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
KR20170084202A (ko) * | 2014-11-14 | 2017-07-19 | 노파르티스 아게 | 항체 약물 접합체 |
PT3221346T (pt) | 2014-11-21 | 2020-10-23 | Bristol Myers Squibb Co | Anticorpos compreendendo regiões constantes de cadeia pesada modificadas |
TN2017000203A1 (en) | 2014-11-21 | 2018-10-19 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
KR20220131527A (ko) * | 2020-01-10 | 2022-09-28 | 크링 바이오테라퓨틱스 비.브이. | 상피 카드헤린-특이적 항체 |
WO2024013315A1 (en) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
CA2345160A1 (en) | 2001-04-25 | 2002-10-25 | Roy Fenwick | Multifunctional flower pot |
EP1402256A4 (en) * | 2001-05-31 | 2006-09-13 | Chiron Corp | USE OF P-CADHERIN AS TARGET IN ANTICANCER THERAPY |
EP1446501A2 (en) | 2001-06-25 | 2004-08-18 | Buadbo APS | Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
JP2006089471A (ja) | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン2抗体と機能性核酸の使用 |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
CN101193916B (zh) * | 2004-12-09 | 2012-09-05 | 森托科尔公司 | 抗整联蛋白免疫缀合物、方法和用途 |
WO2006114704A2 (en) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
CN101432303A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗cdh3抗体的效应物功能来损伤细胞的方法 |
WO2008146854A1 (ja) * | 2007-05-28 | 2008-12-04 | National Institute Of Advanced Industrial Science And Technology | 抗モータリン抗体のパラトープ及びエピトープ |
RU2011103199A (ru) * | 2008-06-30 | 2012-08-10 | Онкотерапи Сайенс, Инк. (Jp) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение |
US8455249B2 (en) * | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
DK2519542T3 (da) | 2009-12-28 | 2019-01-14 | Onco Therapy Science Inc | Anti-cdh3-antistoffer og anvendelser deraf. |
-
2011
- 2011-10-28 PT PT11836461T patent/PT2634194T/pt unknown
- 2011-10-28 EP EP11836461.1A patent/EP2634194B1/en active Active
- 2011-10-28 EP EP18182161.2A patent/EP3404043B1/en active Active
- 2011-10-28 EP EP20167547.7A patent/EP3708586A1/en active Pending
- 2011-10-28 DK DK18182161.2T patent/DK3404043T3/da active
- 2011-10-28 RS RS20181024A patent/RS57646B1/sr unknown
- 2011-10-28 SI SI201131559T patent/SI2634194T1/sl unknown
- 2011-10-28 HU HUE11836461A patent/HUE039375T2/hu unknown
- 2011-10-28 LT LTEP11836461.1T patent/LT2634194T/lt unknown
- 2011-10-28 DK DK11836461.1T patent/DK2634194T3/da active
- 2011-10-28 WO PCT/JP2011/074958 patent/WO2012057328A1/ja active Application Filing
- 2011-10-28 PL PL11836461T patent/PL2634194T3/pl unknown
- 2011-10-28 ES ES11836461.1T patent/ES2690469T3/es active Active
- 2011-10-28 US US13/882,453 patent/US9328160B2/en active Active
- 2011-10-28 PL PL18182161.2T patent/PL3404043T3/pl unknown
- 2011-10-28 ES ES18182161T patent/ES2931477T3/es active Active
- 2011-10-28 JP JP2012540965A patent/JP6006640B2/ja active Active
-
2016
- 2016-06-28 JP JP2016127379A patent/JP2016175945A/ja active Pending
-
2018
- 2018-09-07 HR HRP20181438TT patent/HRP20181438T1/hr unknown
- 2018-09-17 CY CY181100957T patent/CY1121061T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
RS57646B1 (sr) | 2018-11-30 |
EP3404043A1 (en) | 2018-11-21 |
JP2016175945A (ja) | 2016-10-06 |
EP2634194A1 (en) | 2013-09-04 |
PT2634194T (pt) | 2018-10-19 |
PL2634194T3 (pl) | 2018-12-31 |
ES2690469T3 (es) | 2018-11-21 |
SI2634194T1 (sl) | 2018-11-30 |
JPWO2012057328A1 (ja) | 2014-05-12 |
WO2012057328A1 (ja) | 2012-05-03 |
PL3404043T3 (pl) | 2023-01-02 |
CY1121061T1 (el) | 2019-12-11 |
JP6006640B2 (ja) | 2016-10-12 |
ES2931477T3 (es) | 2022-12-29 |
DK2634194T3 (da) | 2018-10-01 |
EP2634194B1 (en) | 2018-08-15 |
EP2634194A9 (en) | 2014-04-02 |
EP3404043B1 (en) | 2022-10-26 |
LT2634194T (lt) | 2018-10-25 |
US20130317201A1 (en) | 2013-11-28 |
EP3708586A1 (en) | 2020-09-16 |
US9328160B2 (en) | 2016-05-03 |
EP2634194A4 (en) | 2014-05-28 |
HRP20181438T1 (hr) | 2018-11-16 |
HUE039375T2 (hu) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2023013I1 (el) | Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης | |
LTPA2019011I1 (lt) | CGRP antikūnai | |
LTC2635601I2 (lt) | Antikūnai prieš il-23 | |
HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
BR112012030311A2 (pt) | anticorpo | |
DK3404043T3 (da) | Anti-cdh3-antistof med høj internaliseringskapacitet | |
PL2581113T3 (pl) | Przeciwciało anty-tim-3 | |
BR112013016235A2 (pt) | anticorpo modificado com meia-vida aumentada | |
BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
DK2552261T3 (da) | Propfilter med proprum med aromakugle | |
PT2552242E (pt) | Resumo | |
PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
CO6791565A2 (es) | Anticuerpos anti-notch1 | |
DK3351255T3 (da) | Modificerede anti-cd4-antistoffer | |
EP2637493A4 (en) | Dual mode ratchet pruners | |
DK3202789T3 (da) | Anti-vla-4-antistoffer | |
GB201007957D0 (en) | Antibody | |
UA20723S (uk) | Ємність | |
UA20724S (uk) | Ємність | |
UA20722S (uk) | Ємність | |
GB201017780D0 (en) | Antibody |